Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

For nearly a century, the diagnosis and grading of oligodendrogliomas and
oligoastrocytomas has been based on histopathology alone. Roughly 20 years ago, the first …

Abstract The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate
dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation …

The most frequently mutated metabolic genes in human cancer are those encoding the
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been …

Heterozygous mutations in NADP‐dependent isocitrate dehydrogenases (IDH) define the
large majority of diffuse gliomas and are associated with hypermethylation of DNA and …

Specific point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) occur in a
variety of cancers, including acute myeloid leukemia (AML), low-grade gliomas, and …

Abstract Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to
IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the …

Abstract Mutant isocitrate dehydrogenase 1 (IDH1) catalyzes the production of 2-
hydroxyglutarate but also elicits additional metabolic changes. Levels of both glutamate and …

Mutations in isocitrate dehydrogenase (IDH) 1 are high-frequency events in low-grade
glioma and secondary glioblastoma, and IDH1 mutant gliomas are vulnerable to …

Background The molecular genetic classification of gliomas, particularly the identification of
isocitrate dehydrogenase (IDH) mutations, is critical for clinical and surgical decision …